Repeat adverse events long after percutaneous coronary revascularization in diabetics

Minerva Cardioangiologica

Volumn 58, Issue 1, 2010, Pages 23-34

  Cavallero, E ^a   Biondi Zoccai, G ^a   Mazzanti, A ^a   Moretti, C ^a   Sciuto, F ^a   Omede P ^a   Siliquini, R ^a   Chiado S ^a   Trevi, G P ^a   Sheiban, I ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Coronary artery disease; Diabetes mellitus; Percutaneous transluminal angioplasty

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; RISK ASSESSMENT; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 77952392063     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. World Health Organization (WHO). Global Strategy on diet, physical activity and health: diabetes. Jan 1,2006. [last accessed 2008 November 18; cited 2009 October 161. Available at: http://www.who.int/dietphy-sicalactivity/ publications/facts/diabetes/en/index.htlm/
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
3. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38. (Pubitemid 43974725)
4. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532 (Pubitemid 37176462)
5. Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ et al. Evaluation of Methods and Management of Acute Coronary Events Investigators. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007;28:540-545
6. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501-1508
7. Kutane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus. J Am Coll Cardiol 2008;51:708-715
8. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54.
9. ESC. Guidelines for Percutaneous Coronary Interventions. The Task Force for the Percutaneous Coronary Interventions of the European Society of Cardiology. European Heart Journal 2005;26,804-847
10. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538
11. Cudip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al.; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351
12. Kannel WB, McGree DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
13. Cosgrave J, Melzi G, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM etal. Drug-eluting stent restenosis: the pattern predicts the outcome. J Am Coll Cardiol 2006;47:2399-2404
14. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-1077
15. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV et al.; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-538
16. [No authors listed]. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122-1129
17. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE et al.; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:9G-19G.
18. Kapur A, Malik IS, Bagger JP, Anderson JR, Kooner JS, Thomas M et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 2005;149:13-19
19. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008;155:215-223
20. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997 (Pubitemid 46376799)